Current Therapeutic Options for Pancreatic Ductal Adenocarcinoma

被引：10

作者：

Bisht, Savita ^{[1
]}

Brossart, Peter ^{[1
]}

Feldmann, Georg ^{[1
]}

机构：

[1] Univ Hosp Bonn, Dept Internal Med 3, Bonn, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷 / 10期

关键词：

Chemotherapy; Palliative treatment; Pancreatic cancer; PHASE-III TRIAL; ADJUVANT CHEMOTHERAPY; AMERICAN SOCIETY; NAB-PACLITAXEL; FOLINIC ACID; CANCER; GEMCITABINE; SURVIVAL; RESECTION; OUTCOMES;

D O I：

10.1159/000493868

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Pancreatic cancer remains the fourth most common cause of cancer-related mortality and is a major health threat. The majority of cases are diagnosed at advanced disease stages, limiting the chances of long-term survival. Several new therapeutic regimens have been introduced into routine clinical practice in recent years and a plethora of novel approaches is currently undergoing preclinical and early clinical evaluation. This review discusses the current standards of care for systemic therapy of pancreatic cancer and gives a brief outlook on ongoing clinical trials. (C) 2018 S. Karger GmbH, Freiburg.

引用

页码：590 / 594

页数：5

共 50 条

[1] ASSENAT E, 2017, J CLIN ONCOL S, V36
[2] Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
Burris, HA
Moore, MJ
Andersen, J
Green, MR
Rothenberg, ML
Madiano, MR
Cripps, MC
Portenoy, RK
Storniolo, AM
Tarassoff, P
Nelson, R
Dorr, FA
Stephens, CD
VanHoff, DD
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) : 2403 - 2413
[3] Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement
Callery, Mark P.
Chang, Kenneth J.
Fishman, Elliot K.
Talamonti, Mark S.
Traverso, L. William
Linehan, David C.
[J]. ANNALS OF SURGICAL ONCOLOGY, 2009, 16 (07) : 1727 - 1733
[4] Two Thousand Consecutive Pancreaticoduodenectomies Discussion
Yeo, Charles
Jones, Scott
Riall, Taylor
Fraser, Charles
Cameron, John L.
[J]. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2015, 220 (04) : 536 - 538
[5] Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1 mm of a resection margin
Campbell, Fiona
Smith, Richard A.
Whelan, Philip
Sutton, Robert
Raraty, Michael
Neoptolemos, John P.
Ghaneh, Paula
[J]. HISTOPATHOLOGY, 2009, 55 (03) : 277 - 283
[6] Chapman BC, 2018, J PANCREAS, V19, P75
[7] Defining Venous Involvement in Borderline Resectable Pancreatic Cancer
Chun, Yun Shin
Milestone, Barton N.
Watson, James C.
Cohen, Steven J.
Burtness, Barbara
Engstrom, Paul F.
Haluszka, Oleh
Tokar, Jeffrey L.
Hall, Michael J.
Denlinger, Crystal S.
Astsaturov, Igor
Hoffman, John P.
[J]. ANNALS OF SURGICAL ONCOLOGY, 2010, 17 (11) : 2832 - 2838
[8] Chemoradiation Therapy Sequencing for Resected Pancreatic Adenocarcinoma in the National Cancer Data Base
Colbert, Lauren E.
Hall, William A.
Nickleach, Dana
Switchenko, Jeffrey
Kooby, David A.
Liu, Yuan
Gillespie, Theresa
Lipscomb, Joseph
Kauh, John
Landry, Jerome C.
[J]. CANCER, 2014, 120 (04) : 499 - 506
[9] CONROY T, 2018, 2018 ASCO ANN M
[10] Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas.
Conroy, Thierry
Hammel, Pascal
Hebbar, Mohamed
Ben Abdelghani, Meher
Wei, Alice Chia-chi
Raoul, Jean-Luc
Chone, Laurence
Francois, Eric
Artru, Pascal
Biagi, James Joseph
Lecomte, Thierry
Assenat, Eric
Faroux, Roger
Ychou, Marc
Volet, Julien
Sauvanet, Alain
Jouffroy-Zeller, Claire
Rat, Patrick
Castan, Florence
Bachet, Jean-Baptiste
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (18)

← 1 2 3 4 5 →